|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We conducted two studies to characterize the pharmacokinetic (PK) profile of BGF MDI in patients with COPD: (i) a phase I, open-label, single and chronic (7-day) dosing study (NCT03250182) with one treatment arm (BGF MDI 320/18/9.6 μg); and (ii) a PK sub-study of KRONOS (NCT02497001), a phase III, randomized, double-blind study in which patients received 24 weeks' treatment with BGF MDI 320/18/9.6 μg, glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg, budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, or budesonide/formoterol fumarate dry powder inhaler (BUD/FORM DPI) 320/9 μg.
|
31841699 |
2020 |
|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
To determine the accumulative bronchodilator dose at which patients with stable mild-to-moderate asthma and chronic obstructive pulmonary disease (COPD) achieve similar spirometry responses before and after bronchodilator tests using albuterol via a metered dose inhaler with a valved holding chamber (MDI + VHC).
|
31473748 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We assessed the efficacy and safety of GFF MDI relative to umeclidinium/vilanterol dry powder inhaler (UV DPI) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD).
|
31267366 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Treatments were well tolerated, with pneumonia incidence ranging from 0.5-1.4%.BFF MDI improved lung function <i>versus</i> monocomponents and exacerbations <i>versus</i> FF MDI in patients with moderate to very severe COPD.
|
30220648 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Results confirmed the long-term safety and tolerability of GFF MDI 18/9.6 μg twice-daily in subjects with moderate-to-very severe COPD.
|
28427541 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.
|
31530663 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
CSII seems to produce a small improvement in HbA1c in patients with type 1 diabetes inadequately controlled with MDI.
|
30945047 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
A1C = hemoglobin A1C ANOVA = analysis of variance CGM = continuous glucose monitoring CSII = continuous subcutaneous insulin infusion MDI = multiple daily injection T1D = type 1 diabetes.
|
28156154 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Objective</b> To compare the effectiveness of insulin pumps with multiple daily injections for adults with type 1 diabetes, with both groups receiving equivalent training in flexible insulin treatment.<b>Design</b> Pragmatic, multicentre, open label, parallel group, cluster randomised controlled trial (Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE) trial).<b>Setting</b> Eight secondary care centres in England and Scotland.<b>Participants</b> Adults with type 1 diabetes who were willing to undertake intensive insulin treatment, with no preference for pumps or multiple daily injections.
|
28360027 |
2017 |
|
Bipolar Disorder
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
Bipolar Disorder
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The proportion of time in depression was highest among those who followed a predominant DMI course, whereas total time in mania was greatest in BD with psychotic features and BD-I. and with an MDI course.
|
28503106 |
2017 |
|
Bipolar Disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genetic factors are of major aetiological importance in Bipolar Affective Disorder (BPAD type I and II).
|
8980009 |
1995 |
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
To investigate the role of NLRC5 in the activation and reversion of HSCs induced with transforming growth factor-β (TGF-β) and MDI, and to explore its relationship with liver fibrosis.
|
31293340 |
2019 |
|
Severe chronic obstructive pulmonary disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
We assessed the efficacy and safety of GFF MDI relative to umeclidinium/vilanterol dry powder inhaler (UV DPI) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD).
|
31267366 |
2019 |
|
MAJOR AFFECTIVE DISORDER 2
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 1
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 4
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 6
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 7
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 8
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
MAJOR AFFECTIVE DISORDER 9
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Individuals with BPAD presented higher levels of A. actinomycetemcomitans and P. gingivalis, suggesting that periodontitis could be a co-morbidity frequently found in individuals with BAPD.
|
30207388 |
2019 |
|
Severe chronic obstructive pulmonary disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219).
|
30220648 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our finding indicated that MDI 301 offers the potential for repairing the faulty skin function arising from diabetes.
|
28423369 |
2017 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
Our finding indicated that MDI 301 offers the potential for repairing the faulty skin function arising from diabetes.
|
28423369 |
2017 |
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Restoration of SIRT1 protein was observed in the in vivo spontaneously liver fibrosis reversion model and in vitro MDI (isobutylmethylxanthine, dexamethasone, and insulin)-induced reversed stellate cells, and forced expression of SIRT1 also promoted the reversal of activated stellate cells.
|
26435214 |
2015 |